Dr Sin Chi CHEW
Dr Lingyan WU
Xiao Quan ONG
Wen Huan LING
Fiona Ni Ni MOE
Weng Yan NG
Veerabrahma Pratap SESHACHALAM
Shay Lee CHONG
Primary liver cancer or hepatocellular carcinoma (HCC) imposes significant challenges to healthcare with huge unmet clinical needs. HCC is the second leading cause of cancer-related mortality worldwide in males and 80% of HCC are found in the Asia-Pacific. While early-stage HCC is potentially curable by surgical resection, liver transplantation or radiofrequency ablation, recurrences remain common and limits overall survival. Survival in intermediate stage HCC may be prolonged by loco-regional therapy in advanced HCC by systemic therapies. Overall, clinical outcomes in HCC remain poorer than that of other common cancers due to the lack of efficacious systemic therapies. The biology of HCC is intrinsically challenging as HCC is the common end-point of a number of etiologies with different molecular pathways. In addition, significant heterogeneity also exists within the same tumor.
Concerted research leveraging on an inter-disciplinary approach is therefore required to address these challenges. The Program in Translational and Clinical Liver Cancer Research, led by Prof Pierce Chow, is a multi-institutional and multi-national enterprise with NCCS leading translational research platforms and prospective clinical studies in HCC. Nested within the program is the Secretariat of the Asia-Pacific Hepatocellular Carcinoma (AHCC) Trials Group (17 countries, >50 sites) which in Q3 2022 will coordinate an investigator-initiated multi-national randomized phase II trial involving up to 13 sites in the Asia-Pacific. Other active studies under the AHCC Trials Group include a clinical-translational prospective cohort of patients receiving current best-in-class adjuvant therapeutics (AHCC12), surveillance program of 2,000 patients at risk for HCC (AHCC10) and a parallel cohort of 100 HCC patients (AHCC11). Our current portfolio of clinical studies and translational research platforms include:
Subscribe to our mailing list to get the updates to your email inbox...
30 Hospital Boulevard, 168583 +65 6436 8000